Advertisement
Document › Details
Calliditas Therapeutics AB. (7/24/20). "Press Release: Calliditas Reorganizes Its Management Team".
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has reorganized its management team.
From today, the company’s management team will consist of:
Renée Aguiar-Lucander, CEO
Fredrik Johansson, CFO
Dr Richard Philipson, CMO
Frank Bringstrup, Vice President Regulatory Affairs
Andrew Udell, Head of North America, Commercial
Katayoun Welin-Berger, Vice President Operations
“Calliditas will continue to build and benefit from a broad and highly competent senior team which operates in an integrated manner. As the company has grown there is now need for a smaller and more focused executive group to support this structure and continue to leverage this cross functional expertise.”, said CEO Renée Aguiar-Lucander.
Due to the growing number of employees in the US, Andrew Udell has been appointed as Head of North America, Commercial and will be responsible for implementation and execution of medical affairs, market access, as well as sales and marketing in the US.
For further information, please contact:
Renée Aguiar-Lucander, CEO at Calliditas
Tel.: +46 722 52 10 06, email: renee.lucander@calliditas.com
Mikael Widell, Head of Communications and IR
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on July 24, 2020 at 8:00 a.m. CET.
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
Record changed: 2023-06-05 |
Advertisement
More documents for Calliditas Therapeutics (Group)
- [1] Memo Therapeutics AG. (7/6/21). "Press Release: Memo Therapeutics AG Appoints Seasoned Executives Elias Papatheodorou as Chairman and Dr. Thomas Taapken as Member to Board of Directors". Schlieren....
- [2] Calliditas Therapeutics AB. (8/25/20). "Press Release: Calliditas Appoints Group General Counsel"....
- [3] Calliditas Therapeutics AB. (8/13/20). "Press Release: Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA"....
- [4] Calliditas Therapeutics AB. (7/2/20). "Press Release: Exercise of Over-allotment Option and End of the Stabilization Period"....
- [5] Calliditas Therapeutics AB. (6/5/20). "Press Release: Calliditas Therapeutics Prices Its Initial Public Offering on The Nasdaq Global Select Market in the United States"....
- [6] Calliditas Therapeutics AB. (5/14/20). "Press Release: Calliditas Publicly Files Registration Statement with SEC for a Proposed Initial Public Offering in the United States"....
- [7] Calliditas Therapeutics AB. (6/10/19). "Press Release: Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore"....
- [8] Calliditas Therapeutics AB. (4/5/19). "Press Release: Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics". Stockholm....
- [9] Calliditas Therapeutics AB. (1/8/19). "Press Release: Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America"....
- [10] Genkyotex S.A.. (8/20/18). "Press Release: Genkyotex Secures an up to €7.5 Million Gross Financing to further Expand the Development of Its Lead Product". Archamps....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top